Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Olvi plc: Notification of Managers’ Transactions

Olvi plc                              Stock Exchange Release 18 April 2024 at 2.00 pm Olvi plc: Notification of Managers’ Transactions Person subject to the notification requirementName: Akkel PeepPosition: Other senior managerIssuerName: Olvi plcLEI: 7437003NX7WWVRT6AJ55Initial notificationReference number: 58735/5/4 Transaction detailsTransaction date: 16.4.2024Venue: Outside a trading venueNature of transaction: Receipt of a share-based incentiveInstrument: ShareISIN: FI0009900401Volume: 350 Unit price: 0 EUR Aggregated transactionsVolume: 350

Olvi plc: Notification of Managers’ Transactions

Olvi plc                              Stock Exchange Release 18 April 2024 at 2.00 pm Olvi plc: Notification of Managers’ Transactions Person subject to the notification requirementName: Rissanen MarjattaPosition: Other senior managerIssuerName: Olvi plcLEI: 7437003NX7WWVRT6AJ55Initial notificationReference number: 58726/4/4 Transaction detailsTransaction date: 16.4.2024Venue: Outside a trading venueNature of transaction: Receipt of a share-based incentiveInstrument: ShareISIN: FI0009900401Volume: 650 Unit price: 0 EUR Aggregated transactionsVolume:

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.“We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year’s World Congress of Nephrology,” said Richard Philipson, Chief Medical Officer of Calliditas. “

BioStock: Annexin towards completion of phase II study and share issue

After reporting promising efficacy signals in the ongoing phase II study on patients with the eye disease RVO, Annexin Pharmaceuticals now has a stronger position in licensing and partnership discussions. To finance continued activities, the company also plans to conduct a rights issue of approximately SEK 45 million, with parts of both the board and management intending to participate. BioStock reached out to CEO Anders Haegerstrand for a comment.Read the interview with CEO Anders Haegerstrand here: https://www.biostock.se/en/2024/04/annexin-towards-completion-of-phase-ii-study-and-

BlueNord: Update on Tyra Redevelopment Project

Oslo, 18 April 2024: BlueNord ASA (“BlueNord” or the “Company”) has been informed by the operator TotalEnergies that an operational occurrence related to the IP compressor is temporarily impacting the commissioning of the new Tyra facilities during the ramp-up and testing period, and the teams are working to resolve the issue. Gas export from the Tyra hub to Denmark will continue, however, the operator is currently evaluating the potential impact on the timing to reach full technical capacity. BlueNord will update the market accordingly, including if any impact on BlueNord’s production

Invitation to SRV Group Plc’s January–March 2024 interim report results briefing

SRV GROUP PLC     INVESTOR NEWS     18 APRIL 2024      13:00 EEST Invitation to SRV Group Plc’s January–March 2024 interim report results briefingSRV Group Plc will publish its January–March 2024 interim report on Thursday 25 April 2024 at 8:30 EEST. The release can be found on the company’s website at www.srv.fi/en/investors. SRV will present the financial results to the analysts, investors and representatives of the media at a webcast on the same day, 25 April 2024, starting at 11.00 EEST. The event will be held in Finnish and hosted by CEO Saku Sipola and CFO Jarkko Rantala.

Nokian Tyres will publish its Interim Report for January–March 2024 on April 29, 2024

Nokian Tyres plc Press Release April 18, 2024 at 1:00 p.m. EEST  Nokian Tyres will publish its Interim Report for January–March 2024 on Monday April 29, 2024, approximately at 1:00 p.m. EEST. After publication, the release will be available at www.nokiantyres.com/company/investors/.  A conference call for investors, analysts and media will be held on the publishing day at 2:00 p.m. EEST. In the call, President and CEO Jukka Moisio and CFO Niko Haavisto will present the financial results. Participants can listen to the call online at https://nokiantyres.videosync.fi/2024-q1-results

UPM Raflatac highlights progressive sustainability milestones in 2023 Climate Review

(UPM Raflatac, Helsinki, 18 April 2024 at 13:00 EEST) – UPM Raflatac has today published its 2023 Climate Review, highlighting the significant strides it has taken towards becoming the first label materials company to go beyond fossils. This ambition underscores UPM Raflatac's dedication to sustainability through three key focus areas: enhancing the sustainability of forests and lands, reducing emissions, and continued innovation through its products and service offering. Reducing the use of industrial fossil emissions is the most important way to mitigate climate change. In

Grand Opening for Clas Ohlson in Falkenberg

There was great interest when Clas Ohlson's new store in Falkenberg in Sweden opened at 10 am today. The new store is Clas Ohlson's first in the city."We know that we have been eagerly awaited, and it’s great that the new store is finally open. Now, it will be more convenient for people in Falkenberg to find what they need for their home fixing," says Andreas Helgesson, Country Operations Manager. The new store is located in the centre of Falkenberg in Stortorget shopping mall, which was recently rebuilt for Clas Ohlson's establishment. In connection with the mall, a completely new

Invitation to interim report livestream 25 April

Paradox Interactive hereby invite you to a livestream in connection with the publication of the company’s interim report for January - March for the fiscal year 2024. Fredrik Wester, CEO, and Alexander Bricca, CFO, will host the livestream on Paradox Interactive’s YouTube channel, present the quarter’s results, and answer questions related to the report and the company’s financial performance. Date: 25 April 2024Time: 12:00 PM CEST Link: https://youtube.com/paradoxinteractiveThe interim report will be published at 08:00 CEST on 25 April and will be available at https://www.

Eastnine publishes the English version of the Annual Report 2023

Today Eastnine AB (publ) has published its Annual Report 2023 in English. The report is available on the Company´s website www.eastnine.com. The Swedish original was published on 26 March 2024 and is available on the Company’s website. Eastnine AB (publ) For more information contact: Kestutis Sasnauskas, CEO, +46 8 505 97 700Britt-Marie Nyman, CFO and deputy CEO, +46 70 224 29 35Visit www.eastnine.com

Orkla's Board of Directors and Chair of the Board of Directors elected

The Annual General Meeting of Orkla ASA was held today. All Board members were up for election. The following Board members were re-elected for one year:Stein Erik Hagen, Liselott Kilaas, Peter Agnefjäll, Christina Fagerberg, Rolv Erik Ryssdal and Caroline Hagen Kjos. In addition, the following new Board member was elected for one year:Bengt Arve Rem Stein Erik Hagen was elected as Chair of the Board of Directors, as proposed by the nomination committee. Orkla ASAOslo, 18 April 2024 Ref.: EVP Communication and Corporate AffairsHåkon MageliTel.: +47 928 45 828

Everfuel A/S – Annual General Meeting 2024

Herning, Denmark, 18 April 2024 – The Annual General Meeting 2024 was held today. All the proposed resolutions were approved by the AGM. This includes the re-election of Søren Eriksen, Jørn Rosenlund, Christina Aabo and Anne Kathrine Steenbjerge to the Board of Directors and approval of the resolution to appoint Yasuhiro Miyata a seat in the Board of Directors. The Minutes of Meeting is attached and will be available from the company’s website: www.everfuel.com/investor/ For additional information, please contact Jesper Ejlersen, CFO, Everfuel, jej@everfuel.com Mads T. Mortensen,

Annual General Meeting held

The Annual General Meeting of Orkla ASA was held today, 18 April 2024, as a digital meeting. All proposals on the agenda were adopted, cf. the notice of the Annual General Meeting published as a stock exchange notice on 26 March 2024. The General Meeting approved the Board's proposal to distribute an ordinary dividend for 2023 of NOK 3.00 per share, plus an additional dividend of NOK 3.00 per share. The dividend will be paid on 3 May 2024 to shareholders of record as of the date of the Annual General Meeting. A translation of the minutes from the Annual General Meeting will be

Norse Atlantic Airways Introduces New Route Between London Gatwick and Cape Town

· New London to Cape Town route launches 28[th] October 2024 · Return fares start from just £499 return in Economy and £1199 return in Norse Premium class. · Tickets available to book now on www.flynorse.comNorse Atlantic Airways proudly announces the launch of its newest route connecting London Gatwick and Cape Town, set to commence on October 28th, 2024. With flights operating three times a week on Monday, Wednesday, and Saturday, travellers can now experience the vibrant culture and breathtaking landscapes of Cape Town with ease. With fares starting from just £499 return in

Elkem ASA - Minutes from the annual general meeting 2024

Oslo, 18 April 2024 The annual general meeting of Elkem ASA was held on 18 April 2024 in Oslo. All proposals on the agenda were adopted, cf. the notice of the annual general meeting that was sent to the Oslo Stock Exchange on 22 March 2024. The minutes of the annual general meeting is attached and available on www.elkem.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. For further information, please contact:Odd-Geir LyngstadVP Finance & Investor RelationsTel: +47 976 72 806Email: odd-geir.

BE Group Interim Report January – March 2024

First quarter · Net sales decreased by 16% to SEK 1,305 M (1,558) · The underlying operating result increased to SEK 42 M (10) · The quarter was affected by items affecting comparability of SEK -27 M (-) related to closure of the operations in the Baltics · The operating result increased to SEK 4 M (1), including inventory losses of SEK -11 M (-9) · Result after tax amounted to SEK -4 M (-3) · Cash flow from operating activities amounted to SEK 44 M (226) · Earnings per share amounted to SEK -0.35 (-0.22) Statement from the CEONet sales fell by 16 percent to SEK

Scania Super Green Truck 2024

Each year, all the manufacturers of heavy trucks in Europe are invited to the Green Truck comparison test. It is organised by two German trade magazines to identify the most transport-efficient long-haul truck. Apart from a brief hiccup in 2023 – when Scania came second – the Södertälje-based manufacturer has won and been named “Green Truck” for seven out of the last eight tests. In fact, Scania has won the test nine out of the 14 times that it has been held since the competition began in 2011 – an impressive feat!“Scania participates in many press tests in Europe, but the Green Truck Award

BiBB receives patent approval for EndoDrill in India

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces today that the Indian Patent Office has granted the first patent for EndoDrill[®]. The patent provides broad protection of the EndoDrill[®] system until October 2039.The approved Indian patent 532933 originates from the patent application IN202127017788 from patent family 1 and protects the EndoDrill[®] product series, the world's first market-cleared electric-driven biopsy instrument for endoscopy. BiBB has

Freetrailer expands to the Netherlands

Freetrailer Group A/S is partnering with Christian Tepper, who has a strong digital mindset, and long-lasting experience from within the industry. Christian will front our ambitions in the Netherlands as Sales Manager.The Netherlands has been on the roadmap for a while due to the market maturity within rental of trailers. Freetrailer is ready to escalate operationally, and the area in and around Amsterdam has been selected as our focus when we will be ready with our concept for our partners and end-users in Q1 2025.   For 9 years Christian Tepper was the owner of the second largest

Gradientech strengthens its commercial management team

The diagnostics company Gradientech today announces that AnnaLotta Schiller Vestergren has been appointed as the company’s Chief Commercial Officer and part of the management team. AnnaLotta has extensive experience with international commercial organisations, with nearly 30 years of leading positions in life science and diagnostics.“I´m very pleased to welcome AnnaLotta to join the Gradientech team. With a background in molecular biology and bacteriology and extensive experience in international sales and business development from major life science companies as well as smaller emerging

Spinomenal Debuts Queen of the Amazon Slot

Leading iGaming content provider Spinomenal has released its new hit, Queen of the Amazon. Set amongst the lush rainforest, this 5x4 slot welcomes players on an adventure where treasure awaits intrepid explorers.A majestic Amazon headdress, tiger, gorilla, and snake, make up the Medium symbols on the reels. At the heart of the story stands the queen herself, representing the Wild symbol. Her symbol can substitute for any other symbol on the reels, except for the Free Spins and Bonus symbols. Discovering five Wilds on a winning line will multiply the bet line by 2000.  Synced Reels, where

Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting

Stockholm, April 18, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation in an oral presentation at the 50th Annual meeting of the European Society for Blood and Marrow Trasnplantation (EBMT) held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy agent comprised of an anti-CD45 monoclonal antibody conjugated to Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and

There are no items matching the current filter
There are no more items matching the current filter
Back to top